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Abstract
Angiomyolipoma is a type of  benign renal tumor. It is sporadic and isolated in 80% of  cases. The remaining 20% is associated with tuberous 
sclerosis complex or pulmonary lymphangioleiomyomatosis. Generally, angiomyolipomas manifest themselves as angiomyolipomatosis, in 
which the angiomyolipomas are larger, bilateral, and widespread. Understanding whether angiomyolipomas are present in the context of 
angiomyolipomatosis is of  considerable importance because it might be associated with malignant lesions. This article provides an overview 
of  the radiological features of  renal angiomyolipomatosis under different imaging techniques such as ultrasound, computed tomography, and 
magnetic resonance.
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Introduction
Angiomyolipoma (AML) is a type of  benign renal tumor, 
with an estimated prevalence of  0.3–3% of all renal tumors 
and a greater female predilection (1, 2). It is characteristi-
cally a solid “triphasic” tumor composed of  dysmorphic 
blood vessels, smooth muscle components, and mature 
adipose tissue which may be present in varying amounts 
(3). AML was once considered a hamartoma and, most re-
cently, a choristoma; it is now considered a part of  perivas-
cular epithelioid cell tumors (PEComa) (4–6). PEComa 
are mesenchymal neoplasms formed by nests and sheets 
of  epithelioid and spindle cells that show immunoreactiv-
ity for both smooth muscle and melanocytic markers (7). 
The PEComas now include AML, pulmonary clear cell 
“sugar” tumor and lymphangioleiomyomatosis (LAM), 
primary extrapulmonary sugar tumor, clear cell myomela-
nocytic tumor of  the falciform ligament/ligamentum teres, 
abdominopelvic sarcoma of  perivascular epithelioid cells, 
and other neoplasms with similar characteristics (8). Renal 
angiomyolipomatosis is a common manifestation in patients 
with tuberous sclerosis (TS) and LAM, where AMLs are 
larger, multiple, almost always bilateral, and have a greater 
predisposition to bleeding. AML is sporadic and isolated in 
80% of  cases, while the remaining 20% is associated with tu-
berous sclerosis complex (TSC) or pulmonary LAM (9, 10). 
Radiologically, the sporadic AML is predominantly classi-
fied into classic (common) and fat-poor AML (uncommon). 
Fat-poor AML is further classified into three subtypes: hy-
perattenuating AML (approximately 4.5% of  all AMLs), 
isoattenuating AML (rare), and AML with epithelial cyst 
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Figure 1. CT axial scan of the abdomen during venous phase of a 45-year-old woman with TS showing the presence of renal 
angiomyolipomatosis (A and B) and caliectasia at the level of the left upper calyceal group (A). Furthermore, a cystic lesion with 
solid peripheral tissue indissociable from the left inferior renal pole is evident (B). At the follow-up CT scan performed approx-
imately 6 months later, the cystic lesion showed an increase of the solid component. Consequently, the patient underwent left 
nephrectomy and tumorectomy. Histological examination revealed the diagnosis of dedifferentiated liposarcoma.
(rare). Another type of  sporadic AML is epithelioid AML 
(rare). Syndromic AML is subdivided into AML in TSC 
and AML in LAM (11).The majority (>80%) of  AMLs 
are detected incidentally during imaging. Most patients 
are asymptomatic when AML is diagnosed (10). The most 
common presentation is spontaneous retroperitoneal hem-
orrhage, although this happens in less than 15% of  cases 
(10). Other clinical presentations are anemia, hematuria, 
palpable mass, flank pain, urinary tract infection, or renal 
failure (12, 13). As most classic AMLs do not increase in size 
and remain asymptomatic, the management is conservative. 
However, some grow gradually, showing a growth rate of  5% 
or 0.19 cm per year (14, 15). Oesterling et al. (16) proposed 
an algorithm for the management of  AML based on tumor 
size and symptoms. For small AML (≤ 4 cm), follow-up with 
ultrasound (US) imaging is recommended every 12 months; 
for small AML in symptomatic patients, arterial emboliza-
tion or partial nephrectomy can be chosen although ob-
servation is often favored in clinical practice. Treatment is 
recommended for symptomatic patients with large tumors, 
especially if  the AML has bled. In asymptomatic patients 
with large AML, follow-up with computed tomography 
(CT) or US is recommended (16). Other options introduced 
for AML treatment are transarterial ethanol and percutane-
ous ablation using cryoablation or radiofrequency (17–19).
In this article, we describe the radiological features of renal 
angiomyolipomatosis. A PubMed search was performed by a 
radiologist for the term “angiomyolipomatosis.” The research 
showed 20 articles published in a period from 1969 to 2013. 
A total of 10 articles were excluded: four in German, three in 
French, one in Russian, and two did not describe the radio-
logical features of renal angiomyolipomatosis. The  remaining 
10 articles in English, Italian, and Spanish languages describ-
ing radiological features of renal angiomyolipomatosis were 
selected.
Angiomyolipomatosis in Tuberous Sclerosis 
Complex
Tuberous sclerosis is largely the result of loss-of-function 
mutations of TSC1 (9q34) or TSC2 (16p13.3) genes. In ad-
dition to conditions such as mental retardation and seizures, 
TSC is associated with AMLs, LAM, pulmonary multifocal 
micronodular hyperplasia, subependymal giant cell tumors, 
cutaneous angiofibromas, and cardiac rabdomyomas (20). 
AMLs occur in 55–75% of patients with TS; AMLs in TS 
typically develop at a young age and are frequently multiple, 
almost always bilateral and larger in size, presenting as an-
giomyolipomatosis (Figure 1) (11, 21). Patients with TSC are 
more likely to show multiple, bilateral, and larger AMLs than 
AMLs in sporadic cases (22, 23). Most of the AMLs in TSC 
manifest as the classic type, while fat-poor AMLs are found 
in over one-third of these patients. Fat-poor AMLs in TSC 
tend to be larger than those of the sporadic form (24).
As renal cell carcinoma may occur in patients with TSC, 
renal masses without visible characteristic adipose tissue 
may require a percutaneous biopsy or closer follow-up (15). 
Patients with TSC have also shown the presence of epithe-
lioid AML and AML with epithelial cysts; TSC patients are 
more likely to show these two variants of AML compared to 
AMLs found sporadically (25, 26). Epithelioid AML shows 
variable biological behavior including malignancy; in fact, 
during adulthood, it can infiltrate adjacent tissue or metasta-
size to the lungs, liver, peritoneum, or bone (27, 28).
As patients with TSC risk premature loss of nephrons due 
to increasing numbers and dimensions of cysts and AMLs, 
selective arterial embolization, percutaneous ablation, or 
partial nephrectomy are preferred conservative therapies for 
the treatment of these lesions (29). Moreover, these patients 
present a high risk of spontaneous hemorrhage; AML >4 
cm and AML aneurysms >0.5 cm are risk factors for AML 
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hemorrhage (30, 31). Approximately 43% of patients with 
TSC may have recurrent AML bleeding, which is not usually 
seen in sporadic AMLs (32, 33). Indeed, angiomyolipoma-
tosis is often associated with multiple spontaneous bleeding 
events. The mTOR inhibitor sirolimus allows the prevention 
of tumor growth and recurrence of bleeding in patients with 
TSC by inhibiting the activation of the mTOR pathway (34). 
Transcatheter embolization is an effective treatment for con-
trolling bleeding in the acute context and can be performed in 
combination with surgery (17).
Angiomyolipomatosis in 
Lymphangioleiomyomatosis
Renal angiomyolipomatosis can be detected in patients 
with LAM, a rare disease characterized by destructive cys-
tic changes in the lungs. Sporadic LAM manifests itself  in 
one in 400,000 adult females; it may also happen in TSC, 
occurring in 30–40% of adult females and rarely in males 
and children (11, 35). In addition to renal AMLs, LAM 
presents other disorders including lymphangioleiomyomas, 
abdominal lymphadenopathy, and chylous ascites, and an in-
crease in the frequency of meningioma (11, 35–38). As well 
as sporadic AMLs, the guidelines for LAM patients with 
AMLs recommend US examination per year for small AMLs 
(<4 cm), while larger AMLs and AMLs with aneurysms of 5 
mm or greater diameter should be checked twice a year with 
US examination. The treatments of choice for a bleeding 
AML are renal arterial embolization and partial nephrec-
tomy. Furthermore, the mTOR inhibitor sirolimus reduces 
the  volume of AML (34, 35, 39).
Imaging Features of Angiomyolipomatosis
Several studies have described the radiological features of 
angiomyolipomatosis; for this review, we analyzed the radio-
logical features described in several clinical cases. Imaging 
features of the cases of renal angiomyolipomatosis described 
in the literature are listed in Table 1 (40–49).
Renal angiomyolipomatosis generally occurs with multi-
ple and diffuse AMLs, bilaterally localized. Often the masses 
extend almost entirely covering the abdomen, displacing the 
Table 1. Imaging features of cases of renal angiomyolipomatosis
References Imaging method Imaging features
Segal et al. (40) Angiography Hypervascular
Renal enlargement
Deformed calyces
Ahuja et al. (41) Radiography Thick mass of soft tissue with many thin cloud-like calcification 
figures
Excretory urogram Marked congestion and stenosis of the left ureteral outlet
Left kidney well delimited
Right calico-pielic cavities deformed
Right kidney not well defined
Angiography Prominent vascular tortuosity with aneurysmal dilatation at lower 
pole of the left kidney
Altered vascular architecture with peripheral ectasies and microan-
eurysm of the right kidney; furthermore, the lower pole showed a 
region with a roundish morphology, highly vascularized, sur-
rounded by wide arteries and a number of blood pools 
Delayed passage time
Kalra et al. (42) Ultrasound Dimensional increase of the kidneys
Multiple bilateral echogenic masses
Contrast enhancement com-
puted tomography
Numerous irregular hypodense areas of adipose tissue density
Numerous isodense to hyperdense areas varying from soft tissue 
density to blood density
Poor excretion of contrast medium
(Continued )
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Table 1. (Continued )
References Imaging method Imaging features
Granata et al. (43) Ultrasound and 
color-power-doppler
(first patient)
Dimensional increase of the kidneys
Hyperechogenic parenchyma
No evidence of cortico-medullary differentiation
Absence of localized hypervascularization areas
Four renal cysts
Hypoechoic area in the right upper pole
Contrast enhancement 
magnetic resonance imaging
(first patient)
Coarse localized mass at the right upper pole of difficult interpre-
tation. The differential diagnosis was with fat-poor AML, epithe-
lioid AML, and renal cell carcinoma;
biopsy examination showed a diagnosis of fat-poor AML
Ultrasound
(second patient)
Dimensional increase of the kidneys
Irregular profiles of the kidneys
Structural subversion of the renal parenchyma with numerous and 
coarse nodules that alter to cysts
Magnetic resonance imaging
(second patient)
Numerous bilateral AMLs
Liu et al. (44) Unenhanced computed 
tomography
Huge bilateral masses consisting primarily of adipose tissue
Ponce Díaz-Reixa 
et al. (45)
Ultrasound and contrast 
enhancement computed 
tomography (first patient)
Bilateral AMLs
Ultrasound 
(second patient)
Nodule of the right kidney isoecogenous compared to perirenal 
adipose tissue
Contrast enhancement com-
puted tomography
(second patient)
Mass at the right kidney, with heterogeneous appearance and adi-
pose areas in the context, highly suggestive of AML
Histological and immunohistochemical examination confirmed the 
diagnosis of AML
Computed tomography
(third patient)
Mass at the right kidney, compatible with AML
Histological examination of the tumor demonstrated AML with 
epithelioid areas with infiltration of two lymph nodes that showed 
the same histological diagnosis
Er et al. (46) Unenhanced computed 
tomography
Bilateral, renal masses (massive in the right kidney), with the den-
sity of adipose tissue
Incedayi et al. (47) Ultrasound Multiple bilateral hyperechogenic renal masses
Unenhanced computed 
tomography
Massive renal masses 
Fluid accumulation and high-density areas at the right kidney, 
developed following the previous hemorrhage
Stallone et al. (48) Ultrasound Multiple renal hyperechogenic lesions
Contrast enhancement com-
puted tomography
Multiple renal lesions, describing a framework compatible with 
angiomyolipomatosis. Histological analysis confirmed the diagno-
sis of angiomyolipomatosis
Vergnani et al. (49) Unenhanced computed 
tomography
Widespread angiomyolipomatosis in the context of which fat com-
ponents and soft-tissue tumor components were evident; hemato-
mas were also present
AML, angiomyolipoma.
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intestine. Signs of previous bleeding may be present. Renal 
cysts could also be detected. In AMLs with a predominantly 
fatty component, the adipose tissue localized within these le-
sions assumes fundamental importance in the diagnosis. On 
US examination, it appears hyperechoic compared to renal 
cortex. In CT examination, it appears as hypodense area of 
adipose tissue density, mixed, or with soft-tissue attenuation 
due to vascular or smooth muscle components, hemorrhage 
or fibrosis (2).
Bosniak described the angiographic features of AML. The 
author observed three patterns in particular: aneurysmal and 
tortuous vessels, berry-like aneurysms, and slow-flowing ves-
sels with contrast medium retention (50).
On magnetic resonance imaging (MRI), it appears isoin-
tense compared with fat on T1-weighted images; moreover, 
with the use of  in-phase and opposed-phase imaging, AMLs 
with predominant adipose component show the characteris-
tic India ink artifact that appears at the interface between the 
lesion and the normal renal parenchyma on opposed-phase 
T1-weighted images. In T2-weighted images, however, the 
intensity can be variable, depending on the amount of  ad-
ipose tissue present in the lesion, resulting homogeneously 
high in AMLs with a higher adipose component (Figure 2) 
(51–54).
The diagnosis is more difficult if  there is the presence of 
fat-poor AML, epithelial AML, and AML with epithelial 
cysts, as we must discriminate these lesions from malignant 
lesions, such as renal cell carcinoma or the same epithelioid 
AML with malignant biological behavior, being able to be 
present in renal angiomyolipomatosis. For example, it is dif-
ficult to differentiate fat-poor AML from other solid tumors, 
especially renal cell carcinoma. In this case, double-echo gra-
dient-echo chemical-shift MRI could be used in which the 
values of the signal intensity are measured on the renal le-
sion and on the spleen in on-phase and opposed-phase T1-
weighted gradient-echo MRI (54). The presence of small 
calcifications within the lesion, which can be easily detected 
with CT, is considered to be suggestive of renal cell carci-
noma (55). Furthermore, central necrosis is indicative of 
renal cell carcinoma, this being frequently present in medi-
um-to-large clear cell renal cell carcinoma and very rare in 
AML. In fat-poor AML, the low amounts of adipose tissue 
can be detected on opposed-phase and in-phase imaging. 
It also appears homogeneously hypointense on T2-weighted 
images (53).
Finally, even contrast enhancement US can be used in the 
differential diagnosis between malignant and benign renal 
lesions (56). In a retrospective study, Lu et al. found a slow 
Figure 2. MRI axial scan of  the abdomen shows two AMLs of  the left kidney. (A) Opposed-phase shows the charac-
teristic  India ink artifact of  the AMLs. (B) AMLs appear hyperintense on T2-weighted images and (C) hypointense on 
T2-weighted images with fat suppression. (D) T1-weighted image with fat suppression shows contrast enhancement of  the 
AMLs.
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Figure 3. Unenhanced CT axial scan of the abdomen (A and C) and CT of the abdomen during arterious phase (B and D) of 
a 53-year-old woman showing the presence of classic AMLs, recognizable by the adipose component of the lesion.
centripetal enhancement in the cortical phase and a homoge-
neous enhancement in the peak phase in fat-poor renal AML 
(57).
Radiologic Diagnosis of Renal Angiomyolipoma
Jinzaki et al. proposed an AML classification in which clin-
ical features, radiologic features, and pathologic features co-
exist. This section focuses on the radiologic characteristics 
indicated in the AML classification of Jinzaki et al. (11).
Classic angiomyolipoma
Classic AML is a subtype of triphasic AML. The typical 
characteristic of classic AML is the presence of abundant 
adipose tissue (11). This AML almost always appears mark-
edly hyperechoic compared to the renal parenchyma. In ad-
dition, 21–33% of AMLs smaller than 3 cm show acoustic 
shadowing (58, 59). The fat present in AML can be identified 
on unenhanced CT with a region of interest (ROI) showing 
an attenuation less than −10 HU (Figure 3) (50, 60, 61). The 
CT features of classic AML vary due to variable amounts 
of the three components present in the lesion (11). Further-
more, intralesional hemorrhage may be present, especially in 
tumors larger than 4 cm (62). MRI can be used to diagnose 
AML also by detecting fat cells; India ink artifact visible with 
a loss of signal at the boundary between the mass and the 
renal parenchyma is indicative of AML (52).
Differential diagnosis of classic AML is with renal cell car-
cinoma, Wilms tumor, and retroperitoneal liposarcoma and 
teratoma (11).
Fat-poor angiomyolipoma
Fat-poor AMLs are those triphasic AMLs that contain too 
little fat to be identified with unenhanced CT (4, 63). There 
are three subtypes of fat-poor AML; their subdivision is 
based on the number of fat cells and their distribution within 
the lesion; they are hyperattenuating and isoattenuating 
AMLs, and AML with epithelial cysts (64).
Hyperattenuating angiomyolipoma
Hyperattenuating AML makes up about 4–5% of all AMLs 
(65). This subtype of fat-poor AML is generally small, with 
an average of 3 cm of diameter, and accounts for only 4% 
(3–10% range) of fat cells (65–67). As there is an abundant 
amount of smooth muscle component, they present char-
acteristics similar to those of smooth muscle: they appear 
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hyperattenuating compared to renal parenchyma on unen-
hanced CT (usually greater than 45 HU); T1-hypointense 
and T2-hypointense on MRI; no signal loss on fat-sup-
pressed pulse sequences, and chemical shift suppression; and 
isoechoic on US, with one study suggesting could be hyper-
echoic (65–67). Differential diagnosis of hyperattenuating 
AML is with renal cell carcinoma (typically the papillary 
renal cell carcinoma), metastases, oncocytoma, lymphoma, 
metanephric adenoma, and leiomyoma (63, 68).
Isoattenuating angiomyolipoma
Isoattenuating AMLs possess CT attenuations similar to 
those of  the renal parenchyma on unenhanced CT. This 
type of  AML does not possess regions of  adipose tissue at-
tenuation at unenhanced CT. In particular, fat cells are dis-
persed between smooth muscle and vessel components, too 
few to be detected with imaging but in sufficient quantities 
to reduce the overall attenuation compared to hyperattenu-
ating AML (69). On MRI, this subtype of  fat-poor AML 
appears typically T2-hypointense. This feature is given by 
its smooth muscle component (70). Furthermore, Jinzaki 
et al. claim that isoattenuating AML characteristics on all 
MRI pulse sequences are not well known because it is a rare 
lesion; this lesion may or may not show signal loss on fat-
suppressed pulse sequences; the loss of  signal depends both 
on the quantity and the distribution of  fat cells within the 
lesion (11). It also shows chemical shift suppression (54, 70). 
Jinzaki et al. also state that, based on their experience, isoat-
tenuating AML appears slightly hyperechoic on US (11). 
Differential diagnosis of  isoattenuating AML is with renal 
cell carcinoma (11).
Angiomyolipoma with epithelial cysts
AML with epithelial cysts is a very rare variant of  the fat-
poor AML which contains epithelial-lined cysts. These 
AMLs have very few or no fat cells (71). This subtype of 
AML is benign and more common in female (69, 71–74). 
AML with epithelial cysts contains smooth muscle compo-
nent, which represents the predominant component, and 
epithelial cysts and subepithelial stroma, which are typical 
of  this subtype of  fat-poor AML (69, 72). The imaging 
features of  AML with epithelial cyst are not fully under-
stood. A case was described in which the lesion presented 
a small cyst, and a non-cystic part that enhanced homoge-
neously. This lesion appeared hyperattenuating on unen-
hanced CT and, on MRI, T2-hypointense for the smooth 
muscle component (71). Another case described a multi-
locular cystic mass with the cystic component separated 
from that smooth muscle (73). Differential diagnosis is 
with multilocular cystic renal cell carcinoma, multilocular 
cyst, cystic nephroma, and a mixed epithelial and stromal 
tumor (73, 75).
Epithelioid angiomyolipoma
Epithelioid AML is a subtype of extremely rare potentially 
malignant AML (3, 25). Male and female are equally affected 
and the average age is 38 years (3). Approximately one-third 
has local extension or metastasis at diagnosis (76). Epithe-
lioid AML contains numerous atypical epithelioid muscle 
cells; in most of these lesions there are few or no fat cells (25, 
77, 78). This AML subtype typically appears as large masses 
(≥5 cm in size) with intralesional hemorrhage and necrosis; 
it can also be detected as spontaneous perirenal hematoma 
(79–85). These lesions may show small foci of adipose tissue 
on CT or MRI; moreover, epithelioid AML appears hyperat-
tenuating on unenhanced CT (typically greater than 45 HU) 
and T2-hypointense (due to epithelioid muscle component) 
(83, 84). Furthermore, this AML subtype may appear as solid 
masses that enhance homogeneously or heterogeneously or 
as multilocular cystic masses (84). Differential diagnosis of 
epithelioid AML is with renal cell carcinoma and cystic renal 
cell carcinoma (25, 77, 84).
New Radiologic Classification of Renal 
Angiomyolipoma
Song et al. classified renal AML into fat-rich, fat-poor, and 
fat-invisible AML based on the amount of fat detected by 
CT or MRI (86). Fat-rich AML was identified by attenua-
tion value less than or equal to −10 HU obtained by placing 
a ROI in the most hypodense area of the lesion (61). When 
the most hypodense area showed attenuation value greater 
than −10 HU, the chemical shift imaging was evaluated. Tu-
mor-to-spleen ratio and signal intensity index were calculated 
using the values  obtained by placing the ROI in the most hy-
pointense area on opposed-phase images. Fat-poor AML 
was detected when the tumor-to-spleen ratio was <0.71 or 
when the signal intensity index value  was >16.5%. Fat-invis-
ible AML was detected when the tumor-to-spleen ratio was 
≥0.71 and when the signal intensity index value  was ≤16.5% 
(86). Both fat-poor AML and fat-invisible AML exhibit at-
tenuation values greater than –10 HU on unenhanced CT. 
Song et al. showed that the attenuation value of fat-invisible 
AML detected in the ROI located in the most hypodense area 
of the lesion was greater than that of the fat-poor AML (86).
Conclusion
Renal angiomyolipomatosis is a common manifestation 
in  patients with TS and LAM. AMLs are larger, multiple, 
 almost always bilateral, and have a greater predisposition 
to bleeding, which is the reason why follow-up must be per-
formed in these patients. Furthermore, specific subtypes of 
AML, such as poor-fat AML, are difficult to distinguish 
from malignant lesions. For this reason, further imaging ex-
aminations must be performed to obtain further information 
on the nature of the lesions.
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